A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)p yridin-2-yl]1H-indole-5-carbonitrile 701

Details for Australian Patent Application No. 2008241602 (hide)

Owner AstraZeneca AB

Inventors Jansson, Annette; Hedberg, Martin; Thiering, Swantje; Radevik, Andreas; Ryberg, Per; Delisser, Vern

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2008241602

PCT Pub. Number WO2008/130312

Priority 60/912,527 18.04.07 US

Filing date 17 April 2008

Wipo publication date 30 October 2008

Acceptance publication date 2 February 2012

International Classifications

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/5355 (2006.01) - Non-condensed oxazines containing further heterocyclic rings

C07D 213/38 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

Event Publications

29 October 2009 PCT application entered the National Phase

  PCT publication WO2008/130312 Priority application(s): WO2008/130312

2 February 2012 Application Accepted

  Published as AU-B-2008241602

31 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008241604-Xanthine compounds having a positive allosteric GABAB receptor modulator effect

2008241601-Coaxial coupling with by-pass valve and coupling mechanism with bayonette form